Strategies to improve the immunosuppressive properties of human mesenchymal stem cells

Myoung Woo Lee; Somi Ryu; Dae Seong Kim; Ki Woong Sung; Hong Hoe Koo; Keon Hee Yoo

doi:10.1186/s13287-015-0178-y

Strategies to improve the immunosuppressive properties of human mesenchymal stem cells

Myoung Woo Lee, Somi Ryu, Dae Seong Kim, Ki Woong Sung, Hong Hoe Koo, Keon Hee Yoo

Department of Pediatrics

Sungkyunkwan University

Research output: Contribution to journal › Review article › peer-review

44 Scopus citations

Abstract

Mesenchymal stem cells (MSCs) are of particular interest for the treatment of immune-related diseases because of their immunosuppressive capacities. However, few clinical trials of MSCs have yielded satisfactory results. A number of clinical trials using MSCs are currently in progress worldwide. Unfortunately, protocols and methods, including optimized culture conditions for the harvest of MSCs, have not been standardized. In this regard, complications in the ex vivo expansion of MSCs and MSC heterogeneity have been implicated in the failure of clinical trials. In this review, potential strategies to obtain MSCs with improved immunosuppressive properties and the potential roles of specific immunomodulatory genes, which are differentially upregulated in certain culture conditions, will be discussed.

Original language	English
Article number	179
Journal	Stem Cell Research and Therapy
Volume	6
Issue number	1
DOIs	https://doi.org/10.1186/s13287-015-0178-y
State	Published - 7 Oct 2015

Access to Document

10.1186/s13287-015-0178-y

Cite this

@article{0eaf0367335146ac8520837aed6adbc3,

title = "Strategies to improve the immunosuppressive properties of human mesenchymal stem cells",

abstract = "Mesenchymal stem cells (MSCs) are of particular interest for the treatment of immune-related diseases because of their immunosuppressive capacities. However, few clinical trials of MSCs have yielded satisfactory results. A number of clinical trials using MSCs are currently in progress worldwide. Unfortunately, protocols and methods, including optimized culture conditions for the harvest of MSCs, have not been standardized. In this regard, complications in the ex vivo expansion of MSCs and MSC heterogeneity have been implicated in the failure of clinical trials. In this review, potential strategies to obtain MSCs with improved immunosuppressive properties and the potential roles of specific immunomodulatory genes, which are differentially upregulated in certain culture conditions, will be discussed.",

author = "Lee, \{Myoung Woo\} and Somi Ryu and Kim, \{Dae Seong\} and Sung, \{Ki Woong\} and Koo, \{Hong Hoe\} and Yoo, \{Keon Hee\}",

note = "Publisher Copyright: {\textcopyright} 2015 Lee et al.",

year = "2015",

month = oct,

day = "7",

doi = "10.1186/s13287-015-0178-y",

language = "English",

volume = "6",

journal = "Stem Cell Research and Therapy",

issn = "1757-6512",

publisher = "BioMed Central Ltd",

number = "1",

}

TY - JOUR

T1 - Strategies to improve the immunosuppressive properties of human mesenchymal stem cells

AU - Lee, Myoung Woo

AU - Ryu, Somi

AU - Kim, Dae Seong

AU - Sung, Ki Woong

AU - Koo, Hong Hoe

AU - Yoo, Keon Hee

PY - 2015/10/7

Y1 - 2015/10/7

N2 - Mesenchymal stem cells (MSCs) are of particular interest for the treatment of immune-related diseases because of their immunosuppressive capacities. However, few clinical trials of MSCs have yielded satisfactory results. A number of clinical trials using MSCs are currently in progress worldwide. Unfortunately, protocols and methods, including optimized culture conditions for the harvest of MSCs, have not been standardized. In this regard, complications in the ex vivo expansion of MSCs and MSC heterogeneity have been implicated in the failure of clinical trials. In this review, potential strategies to obtain MSCs with improved immunosuppressive properties and the potential roles of specific immunomodulatory genes, which are differentially upregulated in certain culture conditions, will be discussed.

AB - Mesenchymal stem cells (MSCs) are of particular interest for the treatment of immune-related diseases because of their immunosuppressive capacities. However, few clinical trials of MSCs have yielded satisfactory results. A number of clinical trials using MSCs are currently in progress worldwide. Unfortunately, protocols and methods, including optimized culture conditions for the harvest of MSCs, have not been standardized. In this regard, complications in the ex vivo expansion of MSCs and MSC heterogeneity have been implicated in the failure of clinical trials. In this review, potential strategies to obtain MSCs with improved immunosuppressive properties and the potential roles of specific immunomodulatory genes, which are differentially upregulated in certain culture conditions, will be discussed.

UR - https://www.scopus.com/pages/publications/84943250221

U2 - 10.1186/s13287-015-0178-y

DO - 10.1186/s13287-015-0178-y

M3 - Review article

C2 - 26445096

AN - SCOPUS:84943250221

SN - 1757-6512

VL - 6

JO - Stem Cell Research and Therapy

JF - Stem Cell Research and Therapy

IS - 1

M1 - 179

ER -

Strategies to improve the immunosuppressive properties of human mesenchymal stem cells

Abstract

Access to Document

Other files and links

Fingerprint

Cite this